Trial design and participants’ baseline characteristics
NCT05378022
The trial was conducted from December 2020 to April 2022, starting with a cohort of 100 patients equally assigned into two groups: the control group who received standard care, and the Navax group who received LiveSpo Navax in addition to standard care. Each group received 3 sprays of either control 0.9% NaCl or LiveSpo Navax daily. At the end of treatment period, 48 patients in the control group and 44 patients in the Navax group were included in final analysis (Fig. Diagram showing the NCT05378022 clinical trial design and data analysis from December 2020 to April 2022.Patients’ demographic, clinical and sub-clinical characteristics were shown in Table Demographic and clinical characteristics of influenza-infected children before, during and at the end of treatment.–Sub-clinical characteristics of influenza-infected children before treatment and treatment therapy.- Oral administrative drugs: antipyretic paracetamol (Efferegant); expectorant Carbocysteine (Carbothiol); antiviral Oseltamivir phosphate (Tamiflu); antibiotics e.g. cefotaxim (Goldcefo), Amoxicillin/acid clavulanic (Augmentin) based on the results of antibiotic susceptibility test- Aerosol therapy: bronchodilator e.g. salbutamol (Ventolin inhaler) or budesonide (Pulmicort Respules)–